Copper selective 8-aminoquinoline based tetradentate chelators as anticancer agents

IF 3.597 Q2 Pharmacology, Toxicology and Pharmaceutics MedChemComm Pub Date : 2024-06-04 DOI:10.1039/D4MD00171K
Yingzhen Guan, Michel Nguyen, Anne Robert, Yan Liu and Bernard Meunier
{"title":"Copper selective 8-aminoquinoline based tetradentate chelators as anticancer agents","authors":"Yingzhen Guan, Michel Nguyen, Anne Robert, Yan Liu and Bernard Meunier","doi":"10.1039/D4MD00171K","DOIUrl":null,"url":null,"abstract":"<p >Cancer cell proliferation and metastasis are known to be dependent on angiogenesis which is regulated by several parameters including copper availability. Tetradentate monoquinoline (TDMQ) ligands constitute a series of chelators tailored to regulate copper homeostasis due to their specificity for copper(<small>II</small>) with respect to Cu(<small>I</small>) or other biometals like iron or zinc. One of these chelators, TDMQ20 efficiently inhibits both proliferation and migration of several human cancer cell lines, better than the reference drug 5-fluorouracil, and with higher selectivity indexes with respect to non-cancer human cells. The biological activity of TDMQ20 may be driven by the coordination chemistry of copper, and the ability of this chelator to restore copper homeostasis and its subsequent redox properties. The anticancer mechanism of action of TDMQ20 involves intracellular production of reactive oxygen species, drastic mitochondrial damages and induction of tumor cell apoptosis. These data support the selection of TDMQ20 as drug-candidate against several human cancers.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 9","pages":" 3048-3056"},"PeriodicalIF":3.5970,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2024/md/d4md00171k?page=search","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2024/md/d4md00171k","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Cancer cell proliferation and metastasis are known to be dependent on angiogenesis which is regulated by several parameters including copper availability. Tetradentate monoquinoline (TDMQ) ligands constitute a series of chelators tailored to regulate copper homeostasis due to their specificity for copper(II) with respect to Cu(I) or other biometals like iron or zinc. One of these chelators, TDMQ20 efficiently inhibits both proliferation and migration of several human cancer cell lines, better than the reference drug 5-fluorouracil, and with higher selectivity indexes with respect to non-cancer human cells. The biological activity of TDMQ20 may be driven by the coordination chemistry of copper, and the ability of this chelator to restore copper homeostasis and its subsequent redox properties. The anticancer mechanism of action of TDMQ20 involves intracellular production of reactive oxygen species, drastic mitochondrial damages and induction of tumor cell apoptosis. These data support the selection of TDMQ20 as drug-candidate against several human cancers.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
作为抗癌剂的铜选择性 8-氨基喹啉基四价螯合剂
众所周知,癌细胞的增殖和转移依赖于血管生成,而血管生成受包括铜供应在内的多种参数的调节。四价单喹啉(TDMQ)配体构成了一系列专门用于调节铜平衡的螯合剂,因为它们对铜(II)具有特异性,而对铜(I)或铁或锌等其他生物金属则没有特异性。其中一种螯合剂 TDMQ20 能有效抑制几种人类癌细胞株的增殖和迁移,其效果优于参考药物 5-氟尿嘧啶,而且对非癌细胞具有更高的选择性。TDMQ20 的生物活性可能是由铜的配位化学性质、这种螯合剂恢复铜平衡的能力及其随后的氧化还原特性所驱动的。TDMQ20 的抗癌作用机制涉及细胞内活性氧的产生、线粒体的剧烈损伤和诱导肿瘤细胞凋亡。这些数据支持选择 TDMQ20 作为治疗多种人类癌症的候选药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
MedChemComm
MedChemComm BIOCHEMISTRY & MOLECULAR BIOLOGY-CHEMISTRY, MEDICINAL
CiteScore
4.70
自引率
0.00%
发文量
0
审稿时长
2.2 months
期刊介绍: Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry. In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.
期刊最新文献
Back cover Introduction to the themed collection in honour of Professor Christian Leumann Back cover Correction: computational design, synthesis, and assessment of 3-(4-(4-(1,3,4-oxadiazol-2-yl)-1H-imidazol-2-yl)phenyl)-1,2,4-oxadiazole derivatives as effective epidermal growth factor receptor inhibitors: a prospective strategy for anticancer therapy Introduction to the themed collection on ‘AI in Medicinal Chemistry’
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1